By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Development and commercialization of diagnostic tests and biopharmaceutical services131.87M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States423.54M95.01%
International22.23M4.99%